Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
Posts
Novartis News Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
arcticnovartis
Ad hoc announcement pursuant to Art. 53 LR
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia